Donor Stem Cell-Derived Paroxysmal Nocturnal Hemoglobinuria after Umbilical Cord Blood Transplantation

The authors report here a patient with adult T‐cell leukemia/lymphoma, who developed paroxysmal nocturnal hemoglobinuria seven years after umbilical cord blood transplantation.
[European Journal of Haematology]
Abstract
Bookmark

No account yet? Register

0
Share

US FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma

Kite announced that the FDA has granted accelerated approval to Tecartus™, the first and only approved chimeric antigen receptor T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
[Gilead Sciences, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

IL-21 Stimulates the Expression and Activation of Cell Cycle Regulators and Promotes Cell Proliferation in EBV-Positive Diffuse Large B Cell Lymphoma

Analysis of a rare clinical sample of EBV-positive DLBCL, in combination with a NOD/SCID mouse xenograft model, confirmed the effect of IL-21 on the proliferation of EBV-positive diffuse large B cell lymphoma cells.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

0
Share

Characteristics of Cells with Engraftment Capacity within CD34+ Cell Population upon G-CSF and Plerixafor Mobilization

Investigators assessed the hematopoietic stem cell content within the CD34+ fraction of graft samples from three groups of patients: 1-Good Mobilizer patients receiving G-CSF only, 2-Poor Mobilizer (PM) patients receiving G-CSF only, 3-PM patients receiving G-CSF + Plerixafor.
[Leukemia]
Abstract
Bookmark

No account yet? Register

0
Share

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Lisocabtagene Maraleucel (liso-cel)

Bristol Myers Squibb announced that the European Medicines Agency has validated its Marketing Authorization Application for lisocabtagene maraleucel, an investigational CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B after at least two prior therapies.
[Bristol Myers Squibb]
Press Release
Bookmark

No account yet? Register

0
Share

PRDM15 Is a Key Regulator of Metabolism Critical to Sustain B-Cell Lymphomagenesis

Investigators demonstrated that while PRDM15 was largely dispensable for mouse adult somatic cell homeostasis in vivo, it played a critical role in B-cell lymphomagenesis.
[Nature Communications]
Mzoughi, S., Fong, J. Y., Papadopoli, D., Koh, C. M., Hulea, L., Pigini, P., … Guccione, E. (2020). PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis. Nature Communications, 11(1), 3520. https://doi.org/10.1038/s41467-020-17064-0 Cite
Full Article
Bookmark

No account yet? Register

0
Share

GvHD-Free, Relapse-Free Survival Provides Novel Clues for Optimizing Allogeneic-HSCT for Adult T-Cell Leukemia/Lymphoma

The authors performed a nationwide retrospective study of graft-versus-host disease (GvHD)-free, relapse-free survival of patients with allogeneic hematopoietic stem cell transplantation (HSCT)-treated adult T-cell leukemia/lymphoma.
[Bone Marrow Transplantation]
Abstract
Bookmark

No account yet? Register

0
Share

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (Pembrolizumab) for Second-Line Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Merck announced that the FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
[Merck & Co., Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Fate Therapeutics Announces FDA Clearance of IND Application for First-Ever iPSC-derived CAR T-Cell Therapy

Fate Therapeutics, Inc. announced that the FDA has cleared the company’s Investigational New Drug application for FT819, an off-the-shelf allogeneic chimeric antigen receptor T-cell therapy targeting CD19+ malignancies.
[Fate Therapeutics, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

Immunogenomic Landscape of Hematological Malignancies

Researchers integrated over 8,000 transcriptomes and 2,000 samples with multilevel genomics of hematological cancers to investigate how immunological features are linked to cancer subtypes, genetic and epigenetic alterations, and patient survival, and validated key findings experimentally.
[Cancer Cell]
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Identification of the SRC-Family Tyrosine Kinase HCK as a Therapeutic Target in Mantle Cell Lymphoma

Investigators showed that the SRC-family tyrosine kinase hematopoietic cell kinase (HCK), which is primarily expressed in the hematopoietic lineage but not in mature B cells, was aberrantly expressed in mantle cell lymphoma (MCL), and that high expression of HCK was associated with inferior prognosis of MCL patients.
[Leukemia]
Full Article
Bookmark

No account yet? Register

0
Share
Share